OBJECTIVES: Previously, we reported lipid modifying therapy (LMT) and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients at high-risk for cardiovascular events. The objective of the current study was to describe clinical characteristics, lipid modifying therapy (LMT) treatment, and LDL-C attainment of a familial hypercholesterolemia (FH) cohort. METHODS: For this cross-sectional study, the PHARMO Database Network was used. Patients aged ≥18 years with an LDL-C measurement in 2012 (index date) and ≥2 years of continuous enrollment in the pre-index period were considered. We identified FH patients by searching for a diagnosis of FH recorded by a general practitioner (GP) in the 2-year pre-index period or by application of the Dutch Lipid Clinic Network (DLCN) criteria (score ≥6). Patients with a filled prescription for LMT within 45 days of index were considered to be taking the medication. LDL-C goal of ≤100mg/dL was considered at goal. RESULTS: CONCLUSIONS: These data suggest that FH patients in the Netherlands are undertreated by GPs and not at goal. This underscores the need for improving treatment rates with LMT and benefit of add-on treatment options in those not able to achieve goals on current LMTs.